Emcure Pharmaceuticals has reported strong financial results for the second quarter of FY25, with a 20.4% year-on-year increase in revenue to ₹2,002 crore.
The company's focus on both international and domestic markets has contributed to its revenue growth. The international segment experienced a 25% year-on-year growth, with the Canadian market performing exceptionally well at a 51% increase compared to the previous year. The Rest of the World markets also contributed significantly, with a 29% year-on-year growth.
Domestic sales reached ₹933 crore, reflecting a solid 15.4% year-on-year growth.
Emcure's profitability metrics showed improvement, with a 26.1% year-on-year increase in EBITDA and a 38.2% year-on-year growth in Profit After Tax (PAT).
The CEO expressed optimism about the company's performance, highlighting investments made in both international and domestic businesses. Emcure aims to enhance margins through operational efficiencies and drive growth through new product launches and market share gains.
The company's strategic focus on growth and operational synergies, along with its integration of recent acquisitions and partnerships, positions it well in the pharmaceutical industry. Emcure remains committed to delivering value to stakeholders and addressing healthcare needs globally.